August Therapeutics Appoints David Giegel, PhD as Chief Scientific Officer
– Dr. Giegel will guide the development of a novel taste-modifying protein therapeutic to treat eating disorders and obesity –
SAN DIEGO, Calif. July 2, 2019 – August Therapeutics, Inc. announced today that David Giegel, Ph.D. has been appointed to the role of Chief Scientific Officer. In conjunction with this appointment, Dr. Giegel will also become Chair of the Scientific Advisory Board, which he joined in 2018.
Dr. Giegel brings more than twenty-five years of expertise in drug discovery and development to August Therapeutics. He most recently served as President and Chief Scientific Officer of TissueNetix, Inc., a company he founded. Prior to TissueNetix, Dr. Giegel was President and Chief Scientific Officer of MicroStem. Previously, he was an Adjunct Associate Research Professor at San Diego State University, and was Entrepreneur-in-Residence at CONNECT, San Diego, where he mentored companies in the Springboard Program. Dr. Giegel also was Senior Director of the Molecular Sciences Group at Celgene, and held scientific leadership positions at MitoKor, Pfizer, and Warner-Lambert/Parke-Davis. He earned his Ph.D. in Biological Chemistry from the University of Michigan and a B.S. in Chemistry from Miami University in Ohio.
About August Therapeutics, Inc.
August Therapeutics is developing a long-acting protein therapeutic to treat eating disorders and obesity by reducing the pleasure associated with eating flavor-rich foods. We expect the ease of administration (applied directly to the tongue), together with an expected favorable safety profile, will capture a significant share of the multi-billion-dollar Binge Eating Disorder and Obesity markets.
August Therapeutics, Inc.
CEO & Co-founder